secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2021-12-02T23:59:59+00:00
Accession:  0001104659-21-145685
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros sells OMIDRIA franchise to Rayner Surgical for $125M upfront plus milestones and royalties
--------------------------------------------------------------------------------

- Upfront payment of $125M at closing; potential $200M milestone if separate payment secured for four continuous years.
- Royalties: 50% of U.S. net sales until earlier of Jan 1, 2025 or milestone paid, then 30%; 15% on ex-U.S. net sales.
- Transaction valued in excess of $1 billion including royalties; Omeros retains $34M accounts receivable.
- Omeros to focus on complement franchise of MASP-2 and MASP-3 inhibitors.
- Closing expected on or before Dec 31, 2021, subject to HSR waiting period expiration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000110465921145685/0001104659-21-145685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000110465921145685/tm2134414d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-145685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer